

Supplemental Table: Estimated incremental benefits vaccine and harms (myocarditis cases) per million booster doses of Pfizer-BioNTech COVID-19 vaccine, United States, September 2021

Policy consideration and month of benefit-risk assessment	Vaccine/sex/age group (years)	Incremental benefits: COVID-19 outcomes prevented <sup>1</sup>		Harms: adverse events <sup>2</sup>
		Cases	Hospitalizations	Myocarditis
Assessment 5: Pfizer-BioNTech booster COVID-19 vaccine, September 2021 <sup>3</sup>	<b>Females</b>			
	18–29	9,500	114	2
	30–49	10,000	298	2
	50–64	7,500	488	1
	≥65	8,000	2,080	1
	<b>Males</b>			
	18–29	9,500	114	24
	30–49	10,000	298	6
	50–64	7,500	488	1
	≥65	8,000	2,080	1

<sup>1</sup>Outcomes prevented by vaccination compared to those who completed a primary series but not boosted

<sup>2</sup>Ranges presented for harms are based on  $\pm 10\%$  of the reporting rate

<sup>3</sup>A benefit-risk assessment was used to evaluate Pfizer-BioNTech booster in September 2021. Moderna and Janssen COVID-19 booster doses were discussed in October and number needed to vaccinate was used to inform those discussions